机构：[1]Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China[2]Central Laboratory, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan, People’s Republic of China[3]Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China[4]Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China[5]Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
miR-34 family members can form a p53-miR-34 positive feedback loop and induce apoptosis, DNA repair, angiogenesis, and cell cycle arrest. We conducted a case-control study to examine whether two polymorphisms (i.e., rs4938723 in the promoter of pri-miR-34b/c and TP53 Arg72Pro) were linked to the carcinogenesis of cervical cancer among Chinese Han women. Genotypes of the two polymorphisms in 328 cervical cancer patients and 568 control subjects were determined by using a polymerase chain reaction-restriction fragment length polymorphism assay. We found a significantly increased cervical cancer risk in the pri-miR-34b/c rs4938723 under dominant and overdominant model (CT/CC vs. TT: adjusted OR = 1.34, 95 % CI = 1.01-1.77; CT vs. TT/CC: adjusted OR = 1.37, 95 % CI = 1.05-1.80, respectively). Increased cervical cancer risks were also found in the TP53 Arg72Pro under a heterozygous comparison and overdominant model (CG vs. GG: adjusted OR = 1.44, 95 % CI = 1.06-1.95; CG vs. GG/CC: adjusted OR = 1.47, 95 % CI = 1.12-1.94, respectively). Stratification analysis showed that patients carrying the pri-miR-34b/c rs4938723 CT genotype had a significantly increased risk for developing poorly differential status and clinical stage I. Moreover, increased cancer risks were observed for the TP53 Arg72Pro polymorphism in patients with poorly differential status, clinical stage II, and without lymph node metastasis. Combined analysis revealed that the genotypes of rs4938723 CT/CC and TP53 Arg72Pro CG/CC had an increased cervical cancer risk (OR = 2.21, 95 % CI = 1.38-3.53). These findings suggest that the pri-miR-34b/c rs4938723 and TP53 Arg72Pro polymorphisms may contribute to the genesis of cervical cancer.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China[3]Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China[4]Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
推荐引用方式(GB/T 7714)：
Yuan Fang,Sun Ruifen,Chen Peng,et al.Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.[J].Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.2016,37(5):6267-73.doi:10.1007/s13277-015-4467-y.
APA：
Yuan Fang,Sun Ruifen,Chen Peng,Liang Yundan,Ni Shanshan...&Gao Linbo.(2016).Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk..Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,37,(5)
MLA：
Yuan Fang,et al."Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.".Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37..5(2016):6267-73
